Overview
A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
Status:
Completed
Completed
Trial end date:
2013-09-01
2013-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the change of medication satisfaction measured by Medication Satisfaction Questionnaire (MSQ) from baseline to endpoint for patients who are switched into paliperidone palmitate, either immediately or in a delayed mode.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Janssen Korea, Ltd., KoreaTreatments:
Antipsychotic Agents
Paliperidone Palmitate
Criteria
Inclusion Criteria:- Meet diagnostic criteria for schizophrenia according to Diagnostic andStatistical Manual of Mental Disorders Version IV
- Dissatisfied with current medication (Medication Satisfaction Questionnaire score of
less than or equal to 4) or by clinician's judgment and who may benefit from switching
medication
- Have received an oral antipsychotic for at least 4 weeks before randomization
- Agrees to protocol-defined use of effective contraception
Exclusion Criteria:
History of neuroleptic malignant syndrome
- Presence of congenital prolongation of the QT interval - History of treatment with
depot antipsychotics, including long-acting injectable risperidone and paliperidone
palmitate, within 90 days of the screening visit; or any treatment with clozapine
within the previous 60 days
- Any relevant medical history or current presence of systemic disease
- Significant risk of suicidal, homicidal or violent ideation or behavior as clinically
assessed by the investigator